Status:
COMPLETED
Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.
Lead Sponsor:
Kasr El Aini Hospital
Conditions:
Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence
Eligibility:
FEMALE
Phase:
PHASE1
Brief Summary
Evaluation of use of low dose tadalafil 5 mg daily for treatment of female OAB syndrome
Detailed Description
90 female patients with overactive bladder syndrome divided into 3 groups group A subjected to daily low dose tadalafil 5 mg ,group B subjected to tolterodine and group C to placebo. They are evaluate...
Eligibility Criteria
Inclusion
- any female with overactive bladder syndrome, urgency with or without urgency urinary incontinence
Exclusion
- Active Urinary tract infection
- neurologic abnormality
- Pure Stress urinary incontinence
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04500860
Start Date
December 1 2020
End Date
July 1 2022
Last Update
August 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samer Morsy
Cairo, Egypt, 12334